



CGRP monoclonal antibody treatment: Request for reimbursement in Brazil

For reimbursement of part or all of the cost of CGRP monoclonal antibody therapy from payers/insurers in Brazil, it is essential to provide the following information

1st Prescription

A detailed medical report is needed which describes –

- How long the patient has suffered from migraine and migraine frequency and severity
- If available, a headache diary recording migraine attack frequency and severity can be used to support the claim
- Impact of the patient's migraine on their personal and working life and the lives of their family members
- Need for treatment at the Emergency Room or inpatient unit in the last months or years
- Detailed description of previous migraine treatment failures including drug names, doses and duration of treatment

It is also useful to remind payers/insurers that CGRP monoclonal antibodies are approved by the Agência Nacional de Vigilância Sanitária (ANVISA).

2nd and further Prescriptions

A detailed medical report is needed which describes –

- Clear benefits of CGRP monoclonal antibody treatment on patient's migraine frequency and severity
- Impact of treatment on the patient's personal and working life and the lives of their family members
- If available, a headache diary recording migraine attack frequency and severity since CGRP monoclonal antibody treatment started
- Need for treatment at the Emergency Room or inpatient unit since CGRP monoclonal antibody treatment started
- Need for continued therapy for benefits to be maintained

It is again useful to remind payers/insurers that CGRP monoclonal antibodies are approved by the Agência Nacional de Vigilância Sanitária (ANVISA).